double-skinned crabsVietnamese crab exporter
Advertisement
Advertisement
TOPIC

Biomedicine: Policy

Related Topics:
Biomedicine: Policy
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
David Fredrickson, executive vice-president of oncology business at AstraZeneca. Photo: Jonathan Wong
Biomedicine: Industry Trends

Hong Kong needs new funding model to attract global drug makers: AstraZeneca

The pharmaceutical giant has conducted more than 60 clinical trials worth US$25.5 million in the city over the last three years.

videocam
China technology

Chinese biopharma’s global expansion

China technology

China’s R&D spending tops OECD average for first time. What comes next?

13
Biomedicine: Companies

AstraZeneca, Merck, Novo deals inject fresh global momentum into Chinese biotech

Deals involving novel cancer therapies and weight-loss drugs reinforce the growing global appeal of Chinese biotech innovation.

AstraZeneca has moved to advance Chinese biotech firm Akeso’s flagship cancer drug. Photo: Reuters
Hong Kong stock market

‘High tide’ of China biotech deals seen as US curb fears fade: analysts

Stocks jump on reports Washington will allow most licensing deals under ‘substantially softer stance’ than had been feared, analysts say.

videocam
China economy

China’s five-year plan for pharmaceuticals and biomedicine

China aims to become a global drug powerhouse by 2030, according to its five-year development plan for the pharmaceutical and biomedicine sector.

Advertisement
Advertisement
Advertisement
Biomedicine: Industry Trends

Can targeted sound waves transform treatment for pancreatic and brain cancers?

A leading advocate says global trials in pancreatic and brain cancers may yield results within 3 years, with Alzheimer’s another application.

Focused ultrasound is being studied as a non-invasive way to target brain tumours including glioblastoma, an aggressive form of the disease. Photo: Shutterstock
Mainland China

Biomedicine powerhouse: China targets quarter of global first-in-class drugs

New five-year plan aims to turn the sector into a pillar industry by 2030, driven by breakthroughs in technologies across critical fields.

Biomedicine: Companies

ByteDance spin-off Anew Labs raises US$290m amid AI drug design fundraising boom

As AI’s role in drug design advances rapidly, Chinese start-ups are ramping up fundraising efforts.

videocam
Biomedicine: Companies

GSK’s US$750 million cancer drug deal highlights China’s rise as biotech player

The acquisition is the latest in a string of major licensing deals involving Chinese biotechnology firms.

4
GSK has agreed a deal worth up to US$750 million to license a T-cell engager from a Chinese biotechnology firm. Photo: Reuters
Greater Bay Area

Hong Kong targets biomedicine powerhouse status in debut 5-year plan

Tied to the national strategy, the city’s first five-year blueprint doubles down on Greater Bay Area medical tech and healthcare cooperation.

Hong Kong Secretary for Health Lo Chung-mau speaking at the fifth Hong Kong International Biotechnology Conference and Exhibition. Photo: Handout
China technology

China approves string of ‘telepathy’ devices amid push to leapfrog Elon Musk

Chinese regulators have approved a group of brain-technology products this year, as local start-ups push to surpass Musk’s Neuralink.

China’s private sector

Sugar for the pill: US$8b fund boosts Hong Kong’s biotech hub ambitions

Hong Kong Investment Corporation is stepping up its efforts to position itself amid Beijing’s challenge to US pharmaceutical dominance.

China economy

Outside In | China’s export success is a by-product of self-reliance

But while the export surge is an accidental consequence of self-sufficiency and competitive manufacturers, the solution is not protectionism.

videocam
7
Containers sitting stacked at the Port of Shanghai on July 14 in China. Photo: VCG via Getty Images
Science

China biotech sector fears policy backlash after girl dies in gene-editing trial

Scientist says child’s death reveals ‘serious failures in risk assessment, transparency and institutional oversight’.

videocam
Scientists in the biotech sector fear China will impose restrictive regulations after a child died in a gene-editing trial in 2025. Photo: Shutterstock
US-China trade war

Record Chinese biotech out-licensing meets rising US scrutiny

Surging cross-border deals out of China are running headlong into intensifying US national security fears.

videocam
22
China’s private sector

‘Historic breakthrough’: China approves novel drug ahead of US, Japan and Europe

Push to accelerate novel drug reviews promises earlier access to breakthrough therapies for patients long left waiting.

Advertisement
Advertisement
Advertisement
China’s private sector

‘Systemic leap’: China’s drug innovation push yields bumper crop

Home-grown therapies account for 80 per cent of approvals in first six months of the year.

videocam
In addition to surging novel drug development, China’s cross-border deals with global giants show no sign of abating. Photo: Shutterstock
China’s private sector

Europe beckons: can Chinese medical device makers thrive amid trade barriers?

Chinese medical device companies eye Europe for relief from hospital probes at home while navigating protectionism overseas.

China’s private sector

Can AI collaborations power China’s next wave of blockbuster drug deals?

China develops 30 per cent of new therapies worldwide as it rises to the top tier in innovation efficiency, drug supervision official says.

China’s private sector

China’s first AI-powered cancer vaccine production line set to launch in Beijing

Likang Life Sciences says it has developed a personalised vaccine using advanced tech to identify tumour-specific mutations.

The project reflects a global shift in the pharmaceutical sector towards harnessing artificial intelligence. Photo: Shutterstock
China’s private sector

China’s biotech boom: record 5,215 clinical drug trials reported in 2025

Cancer treatments remain the top research focus as Beijing’s drive to make biotech a strategic industry draws attention in Washington.

Cancer research being conducted in a modern lab. Cancer treatments remained the top focus of the record 5,215 clinical drug trials in China last year. Photo: Shutterstock
China’s private sector

Bigger, fewer, tougher: the new era of China-US biotech partnerships

China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.

China’s private sector

Chinese pharmaceutical firms’ cost advantages trump Pentagon blacklist: analysts

Growing collaboration between multinational drug makers and Chinese companies not expected to slow after US move.

China’s private sector

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

Illustration of a healthy lung and a smoker's lung. Photo: Shutterstock
China manufacturing

China extols potential of AI in guideline on marine biopharmaceuticals

Ministry of Natural Resources urges research institutions and drug makers to use the technology to speed up the development of new drugs.

A scientist in a research laboratory. Photo: Shutterstock
Biomedicine: Companies

China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials

The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer.

videocam
China’s private sector

China’s biotech boom drives surge in home-grown innovative drug approvals

Domestic firms dominate China’s drug approvals amid jump in spending and out-licensing deals as regulator speeds path to market.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement